Truist Financial’s Protara Therapeutics TARA Stock Holding History

Truist Financial’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Hold	60,000	–	–	﹤0.01%	2693
2026 Q1	$313K	Buy	60,000 +20,000	+50%	+$118K	﹤0.01%	2361
2025 Q4	$213K	Hold	40,000	–	–	﹤0.01%	2570
2025 Q3	$174K	Hold	40,000	–	–	﹤0.01%	2576
2025 Q2	$121K	Hold	40,000	–	–	﹤0.01%	2483
2025 Q1	$170K	Hold	40,000	–	–	﹤0.01%	2393
2024 Q4	$211K	Hold	40,000	–	–	﹤0.01%	2365
2024 Q3	$73.2K	Buy	40,000 +20,000	+100%	+$41.1K	﹤0.01%	2440
2024 Q2	$41.6K	Hold	20,000	–	–	﹤0.01%	2613
2024 Q1	$80.2K	Buy	+20,000	New	+$64.5K	﹤0.01%	2563

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Truist Financial's TARA Position: Q2 2026 in Review

Truist Financial held its Protara Therapeutics (TARA) position steady in Q2 2026 at 60,000 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #2693.

Truist Financial first reported a position in TARA in Q1 2024 and has held it in 10 quarters since. The position peaked at $313K in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

Truist Financial held 60,000 shares of Protara Therapeutics worth $229K as of Q2 2026.
Truist Financial left its Protara Therapeutics share count unchanged in Q2 2026.
Protara Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2693 holding.
Truist Financial first reported a position in Protara Therapeutics in Q1 2024 and has held it in 10 quarters since.
Truist Financial's Protara Therapeutics position peaked at $313K in Q1 2026.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.